查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018678

抗精神病藥物市場：2026-2032年全球市場預測（依藥物類別、給藥途徑、劑型、適應症及分銷管道分類）

Antipsychotic Drugs Market by Drug Class, Route Of Administration, Formulation, Indication, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，抗精神病藥物市場價值將達到 112.8 億美元，到 2026 年將成長到 122.1 億美元，到 2032 年將達到 196.5 億美元，複合年成長率為 8.25%。

主要市場統計數據
基準年 2025 112.8億美元
預計年份：2026年 122.1億美元
預測年份 2032 196.5億美元
複合年成長率 (%) 8.25%

全面概述了臨床需求、交付模式和相關人員優先事項，這些因素正在改變抗精神病藥物治療的途徑。

抗精神病藥物的治療模式正處於臨床需求、政策壓力和商業性轉型三者交會的十字路口。近年來，分子藥理學的進步、製劑技術的改進以及醫療服務模式的轉變，重塑了臨床醫生和醫療系統治療思覺失調症和雙相情感障礙的方式。患者越來越重視藥物的療效和耐受性，支付方必須證明其具有可證實的價值，而生產商則必須在產品生命週期管理和新產品研發之間取得平衡。

對臨床、技術和證據生成因素相互交織的格局進行分析，這些因素正在重新定義抗精神病藥物治療的範式和相關人員的期望。

抗精神病藥物領域正經歷著一場變革，其驅動力包括以患者為中心的護理模式、藥物創新以及更廣泛的醫療保健系統的現代化。藥物選擇的精準性如今已超越了單純的症狀控制，涵蓋了降低代謝風險、改善認知功能以及促進長期功能恢復等面向。同時，藥物科學的進步催生了新的給藥方案，這些方案能夠提高患者的依從性並降低復發風險，從而改變了住院和門診治療方案的製定標準。

重點評估近期美國關稅變化如何重塑抗精神病藥物商業化的供應鏈策略、採購選擇和競爭地位。

關稅等政策工具會對整個醫藥價值鏈產生顯著的下游影響，尤其是在應用於活性成分、特殊輔料和成品進口時。 2025年，貿易政策的調整將為依賴跨國採購原料藥（API）和成品的製造商和經銷商帶來更大的不確定性。因此，籌資策略正轉向供應商多元化和庫存彈性，同時銷售團隊也重新評估整個分銷管道的服務交付成本。

透過對藥物類別、給藥途徑、分銷管道、劑型和適應症進行合理細分，最佳化臨床引入和商業性重點。

精準的市場區隔能夠清楚展現臨床需求、用藥模式與商業性機會之間的交集。從藥物類別來看，市場可分為第一代抗精神病藥物和第二代抗精神病藥物。第一代藥物包括氯丙嗪、氟奮乃靜、Haloperidol、奮乃靜和硫利達嗪，而第二代藥物包括Aripiprazole、氯氮平、Olanzapine、QuetiapineRisperidone。每類藥物都有其獨特的治療特性、耐受性考量以及處方醫生的偏好，這些都會影響藥物的市場定位策略。

區域戰略訊息，檢驗區域醫療保健系統、報銷框架和獲取趨勢如何影響全球市場抗精神病藥物的採用。

區域趨勢持續以不同方式影響臨床實務、監管解讀和分銷物流。在美洲，醫療服務的發展趨勢包括：重視整合式行為健康服務、擴大社區醫療服務範圍，以及以支付主導的價值評估，這些評估優先考慮療效和成本效益。這些因素影響處方藥的核准決策，並推動了對長效注射劑的投資，尤其是在用藥依從性問題導致不必要用藥的情況下。

一項深入的公司層級分析揭示了產品組合深度、配方創新和策略聯盟如何推動抗精神病藥物領域的競爭優勢。

抗精神病藥物領域的競爭格局反映了傳統產品組合、新型製劑和差異化臨床證據的融合。老字型大小企業憑藉其基礎藥物和廣泛的分銷網路保持著重要的市場佔有率，而專注於創新的製藥公司則致力於提高藥物的耐受性、依從性和長期療效。原廠藥生產商與契約製造生產商之間的合作仍然是擴大生產規模的常見方式，而與技術供應商的合作對於提高依從性和監測解決方案的重要性也日益凸顯。

為製藥公司和相關人員提供切實可行的策略建議，以加強抗精神病藥物治療領域的韌性、證據產生和支付方合作。

產業領導企業應採取協調一致的策略，兼顧短期業務永續營運和長期臨床差異化。首先，他們應透過多元化原料藥（API）和輔料來源、盡可能擴大近岸生產、建立透明的庫存管理和緊急時應對計畫來強化供應鏈。這將有助於降低貿易中斷帶來的風險，並確保所有管道的產品穩定供應。

高度透明的調查方法，結合臨床文獻、專家訪談和供應鏈分析，為合理的策略結論提供了支持。

本研究採用綜合分析方法，結合多面向證據，為策略決策提供透明且可重複的基礎。調查方法透過對同儕審查的臨床研究進行系統性文獻綜述、分析監管指南和附加檔變更，以及與臨床專家、支付者和商業領域觀點進行結構化訪談，從而捕捉真實世界的視角。此外，供應鏈評估利用物流和採購資料來評估採購依賴和區域製造地。

整合作為最終結論，強調臨床差異化、證據產生和強力的商業化策略的協調一致，以實現長期影響。

總之，抗精神病藥物領域正處於轉折點，臨床預期、支付方審查和商業性實施必須緊密結合。製劑和給藥方式的創新正在解決長期存在的依從性和耐受性問題，而數位醫療和真實世界數據（REW）計劃正在重新定義價值的證明方式。同時，不斷變化的貿易政策和日益複雜的供應鏈正迫使製造商重新思考其籌資策略並加強業務永續營運。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：抗精神病藥物市場：依藥物類別分類

  • 第一代抗精神病藥物
    • 氯丙嗪
    • 氟奮乃靜
    • Haloperidol
    • 奮乃靜
    • 硫利達嗪
  • 第二代抗精神病藥物
    • Aripiprazole
    • 氯氮平
    • Olanzapine
    • Quetiapine
    • Risperidone

第9章：抗精神病藥物市場：依給藥途徑分類

  • 注射藥物
    • 肌肉內注射
    • 長效注射藥物
  • 口服

第10章：抗精神病藥物市場（依劑型分類）

  • 口溶錠
  • 解決方案
  • 藥片

第11章：抗精神病藥物市場：依適應症分類

  • 躁鬱症
  • 思覺失調症

第12章 抗精神病藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 抗精神病藥物市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 抗精神病藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 抗精神病藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國抗精神病藥物市場

第17章：中國抗精神病藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Alkermes, Inc.
  • AstraZeneca plc
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Gedeon Richter Plc
  • H. Lundbeck A/S
  • Intra-Cellular Therapies, Inc.
  • Johnson & Johnson
  • Karuna Therapeutics, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Novartis International AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Ltd.
Product Code: MRR-AD36CD897CDF

The Antipsychotic Drugs Market was valued at USD 11.28 billion in 2025 and is projected to grow to USD 12.21 billion in 2026, with a CAGR of 8.25%, reaching USD 19.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.28 billion
Estimated Year [2026] USD 12.21 billion
Forecast Year [2032] USD 19.65 billion
CAGR (%) 8.25%

A comprehensive contextual introduction that frames clinical imperatives, delivery models, and stakeholder priorities transforming antipsychotic therapy pathways

The therapeutic landscape for antipsychotic drugs sits at the intersection of clinical necessity, policy pressures, and commercial transformation. Over recent years, advances in molecular pharmacology, refinements in formulation technology, and shifts in care delivery models have together reshaped how clinicians and health systems approach treatment for schizophrenia and bipolar disorder. Patients increasingly demand tolerability alongside efficacy, payers insist on demonstrable value, and manufacturers must balance lifecycle management with novel product development.

Given this context, strategic stakeholders require a concise orientation that highlights the drivers influencing prescribing behavior, formulary placement, and patient adherence. To that end, it is critical to consider both the legacy role of first generation antipsychotics and the expanding therapeutic footprint of second generation agents, while also recognizing how routes of administration and evolving distribution channels influence real-world access. This introduction frames those dynamics and sets expectations for the deep-dive analyses that follow, emphasizing clinical outcomes, supply chain continuity, and payer engagement as core themes.

An analysis of converging clinical, technological, and evidence-generation forces that are redefining antipsychotic treatment paradigms and stakeholder expectations

The antipsychotic landscape is undergoing transformative shifts driven by patient-centric care models, pharmacological innovation, and broader health system modernization. Precision in agent selection has moved beyond symptomatic control to encompass metabolic risk mitigation, cognitive outcomes, and long-term functional recovery. Concurrently, formulation science has enabled new delivery options that improve adherence and reduce relapse risk, which in turn alters the calculus for hospital and outpatient care planning.

At the same time, digital health tools and telepsychiatry are expanding diagnostic reach and enabling closer monitoring of treatment response and adverse effects. These technologies are fostering shared decision-making between clinicians and patients and are beginning to influence prescribing patterns by making ongoing assessment more practical. Moreover, an emphasis on real-world evidence is changing the evidentiary bar for payer coverage decisions, with health systems increasingly focused on longitudinal outcomes and healthcare utilization metrics rather than isolated trial endpoints. These combined shifts are prompting manufacturers to align clinical development, commercial strategy, and post-market evidence generation more tightly than ever before.

A focused evaluation of how recent United States tariff changes are reshaping supply chain strategies, sourcing choices, and competitive positioning in antipsychotic drug commercialization

Policy instruments such as tariffs can have material downstream effects across the pharmaceutical value chain, particularly when applied to active pharmaceutical ingredients, specialized excipients, and finished dosage imports. In 2025, trade policy adjustments have introduced a period of elevated uncertainty for manufacturers and distributors that rely on cross-border sourcing of APIs and finished products. As a result, procurement strategies are shifting to emphasize supplier diversification and inventory resilience, while commercial teams reassess cost-to-serve assumptions across distribution channels.

These trade-related dynamics also influence the competitive environment. Where tariff pressures increase the landed cost of imported products, manufacturers with domestic or near-shore production capacity can gain relative commercial flexibility. Conversely, companies dependent on complex international supply chains may prioritize contractual hedging, renegotiation with suppliers, and operational investments to mitigate exposure. Trade policy uncertainty can therefore accelerate strategic moves such as localized manufacturing, increased vertical integration of API supply, and closer collaboration with contract manufacturing organizations that have regional footprints. Importantly, clinical programs and regulatory filings remain governed by existing safety and efficacy standards, but timelines for product launches and lifecycle initiatives may be affected by logistical constraints and cost management decisions.

Actionable segmentation insights that align drug class, administration route, distribution channel, formulation, and indication to optimize clinical adoption and commercial focus

Robust segmentation clarifies where clinical need, adoption patterns, and commercial opportunity intersect. By drug class, the market differentiates between first generation antipsychotics and second generation antipsychotics, with first generation agents including Chlorpromazine, Fluphenazine, Haloperidol, Perphenazine, and Thioridazine, while second generation agents include Aripiprazole, Clozapine, Olanzapine, Quetiapine, and Risperidone. Each class presents distinct therapeutic profiles, tolerability considerations, and prescriber preferences that affect positioning strategies.

By route of administration, products are categorized as Injectable and Oral, with Injectable formulations further distinguished by intramuscular and long-acting injectable options; the choice of route directly affects adherence, relapse prevention, and the operational requirements of care settings. Distribution channels encompass Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, which shape patient access models, dispensing practices, and payer interactions. Formulation distinctions such as Orally Disintegrating Tablets, Solution, and Tablets influence patient acceptability and site-of-care decisions. Finally, indication segmentation across Bipolar Disorder and Schizophrenia underscores differences in clinical pathways, treatment duration expectations, and outcomes metrics. Together, these segmentation lenses enable targeted go-to-market approaches, evidence-generation plans, and portfolio prioritization that respond to both clinical and commercial realities.

Regional strategic intelligence examining how distinct healthcare systems, reimbursement frameworks, and access dynamics influence antipsychotic adoption across global markets

Regional dynamics continue to shape clinical practice, regulatory interpretation, and distribution logistics in distinct ways. In the Americas, healthcare delivery trends emphasize integrated behavioral health services, expanding community-based care, and payer-driven value assessments that prioritize outcomes and cost-effectiveness. These factors influence formulary placement decisions and encourage investment in long-acting injectables where adherence challenges drive avoidable utilization.

In Europe, Middle East & Africa, regulatory harmonization efforts coexist with localized reimbursement approaches; this region shows varied adoption speeds for newer agents and formulations based on national health technology assessment processes and funding priorities. Manufacturers must tailor evidence packages and pricing strategies to meet diverse national requirements. In Asia-Pacific, rapid urbanization, evolving insurance coverage, and expanding mental health awareness are creating increased demand for broad access options, including oral therapies and digital adherence tools. Across all regions, supply chain resilience, regulatory compliance, and culturally appropriate patient engagement are critical for successful product launches and sustained uptake. Moreover, geopolitical and policy shifts can introduce regional variability in procurement and distribution that commercial strategies must accommodate.

Insightful company-level analysis revealing how portfolio depth, formulation innovation, and strategic partnerships drive competitive advantage in antipsychotic therapeutics

Competitive positioning in antipsychotic therapeutics reflects a blend of legacy portfolios, novel formulations, and differentiated clinical evidence. Established companies maintain significant presence through foundational agents and broad distribution networks, while specialist innovators focus on improving tolerability, adherence, and long-term functional outcomes. Partnerships between originators and contract manufacturers remain common for scaling production, and alliances with technology providers are increasingly relevant for adherence and monitoring solutions.

R&D pipelines emphasize both incremental innovations-such as improved delivery systems and reformulations-and novel mechanisms targeting symptom domains with better metabolic profiles. Commercial teams that succeed are those which align lifecycle management with real-world evidence accumulation, prioritize payer engagement early, and maintain adaptive supply strategies to mitigate trade and sourcing volatility. Additionally, talent investment in regulatory affairs and health economics expertise is becoming a core competency, enabling firms to navigate complex reimbursement environments and demonstrate comparative value.

Actionable strategic recommendations for manufacturers and stakeholders to strengthen resilience, evidence generation, and payer-aligned commercialization in antipsychotic care

Industry leaders should pursue a coordinated strategy that balances near-term operational resilience with longer-term clinical differentiation. First, fortify supply chains by diversifying API and excipient sourcing, expanding near-shore manufacturing where feasible, and establishing transparent inventory and contingency planning. This will reduce exposure to trade-related disruptions and support predictable product availability across channels.

Second, invest in formulation and delivery innovations that directly address adherence and tolerability challenges, such as long-acting injectables and orally disintegrating tablets, while pairing these products with digital adherence and monitoring solutions to generate compelling real-world evidence. Third, engage payers proactively by developing outcomes-based evidence packages that reflect longitudinal benefits and reduced healthcare utilization. Fourth, adopt flexible commercial models that tailor distribution strategies to local channel dynamics-whether hospital pharmacy, online pharmacy, or retail pharmacy-and prioritize patient support programs that enhance initiation and persistence. Finally, cultivate cross-functional capabilities in health economics, regulatory strategy, and data analytics to ensure that clinical value propositions translate into reimbursement and sustainable uptake.

A transparent research methodology combining clinical literature synthesis, expert interviews, and supply chain analysis to support defensible strategic conclusions

This research synthesis integrates multi-source evidence to provide a transparent and reproducible foundation for strategic decisions. The methodology combines systematic literature review of peer-reviewed clinical studies, analysis of regulatory guidance and labeling changes, and structured interviews with clinical experts, payers, and commercial leaders to capture real-world perspectives. Additionally, supply chain assessments draw on logistics and procurement data to evaluate sourcing dependencies and regional manufacturing footprints.

Qualitative inputs were triangulated with secondary data on prescribing patterns and care-delivery trends to construct robust thematic conclusions. Wherever possible, findings were validated through expert advisory panels to ensure practical relevance and to surface anticipatory risks. The approach emphasizes traceability in data sourcing and clarity in analytical assumptions, enabling stakeholders to interpret conclusions within the appropriate clinical and commercial context. Limitations include the dynamic nature of policy and tariff environments, which necessitates periodic reassessment as trade and regulatory conditions evolve.

A decisive concluding synthesis emphasizing alignment of clinical differentiation, evidence generation, and resilient commercialization strategies for long-term impact

In conclusion, the antipsychotic therapeutics arena is at an inflection point where clinical expectations, payer scrutiny, and commercial execution must be tightly integrated. Innovations in formulation and delivery are addressing longstanding adherence and tolerability challenges, while digital health and real-world evidence initiatives are redefining how value is demonstrated. Concurrently, trade policy developments and supply chain complexities are encouraging manufacturers to reconsider sourcing strategies and to strengthen operational resilience.

Stakeholders who align product development, evidence generation, and market access efforts will be best positioned to capture long-term value. This requires a sustained focus on outcomes that matter to patients and payers, agile commercial planning responsive to regional dynamics, and investment in capabilities that translate clinical differentiation into measurable healthcare benefits. By synthesizing clinical, regulatory, and logistical considerations, organizations can move from reactive planning to proactive strategic execution that supports both patient care and commercial sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antipsychotic Drugs Market, by Drug Class

  • 8.1. First Generation Antipsychotics
    • 8.1.1. Chlorpromazine
    • 8.1.2. Fluphenazine
    • 8.1.3. Haloperidol
    • 8.1.4. Perphenazine
    • 8.1.5. Thioridazine
  • 8.2. Second Generation Antipsychotics
    • 8.2.1. Aripiprazole
    • 8.2.2. Clozapine
    • 8.2.3. Olanzapine
    • 8.2.4. Quetiapine
    • 8.2.5. Risperidone

9. Antipsychotic Drugs Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intramuscular
    • 9.1.2. Long Acting Injectable
  • 9.2. Oral

10. Antipsychotic Drugs Market, by Formulation

  • 10.1. Orally Disintegrating Tablets
  • 10.2. Solution
  • 10.3. Tablets

11. Antipsychotic Drugs Market, by Indication

  • 11.1. Bipolar Disorder
  • 11.2. Schizophrenia

12. Antipsychotic Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Antipsychotic Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antipsychotic Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antipsychotic Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Antipsychotic Drugs Market

17. China Antipsychotic Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Alkermes, Inc.
  • 18.7. AstraZeneca plc
  • 18.8. Dr. Reddy's Laboratories Ltd.
  • 18.9. Eli Lilly and Company
  • 18.10. Gedeon Richter Plc
  • 18.11. H. Lundbeck A/S
  • 18.12. Intra-Cellular Therapies, Inc.
  • 18.13. Johnson & Johnson
  • 18.14. Karuna Therapeutics, Inc.
  • 18.15. Merck & Co., Inc.
  • 18.16. Mylan N.V.
  • 18.17. Novartis AG
  • 18.18. Novartis International AG
  • 18.19. Otsuka Holdings Co., Ltd.
  • 18.20. Pfizer Inc.
  • 18.21. Roche Holding AG
  • 18.22. Sanofi S.A.
  • 18.23. Sumitomo Pharma Co., Ltd.
  • 18.24. Sun Pharmaceutical Industries Ltd.
  • 18.25. Teva Pharmaceutical Industries Ltd.
  • 18.26. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIPSYCHOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FLUPHENAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FLUPHENAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FLUPHENAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HALOPERIDOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HALOPERIDOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HALOPERIDOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY PERPHENAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY PERPHENAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY PERPHENAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIORIDAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIORIDAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIORIDAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ARIPIPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ARIPIPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ARIPIPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLOZAPINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLOZAPINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLOZAPINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY OLANZAPINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY OLANZAPINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY OLANZAPINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY QUETIAPINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY QUETIAPINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY QUETIAPINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RISPERIDONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RISPERIDONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RISPERIDONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY LONG ACTING INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY LONG ACTING INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY LONG ACTING INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORALLY DISINTEGRATING TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORALLY DISINTEGRATING TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORALLY DISINTEGRATING TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY BIPOLAR DISORDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY BIPOLAR DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 168. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 169. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 171. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 172. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 195. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 196. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 198. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 199. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 200. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 203. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 204. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 205. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 207. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 208. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 209. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)